Navigation Links
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Date:10/4/2007

- Patient enrollment to begin in fourth quarter -

SEATTLE, Oct. 4 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that, together with its collaborator Merck Serono, it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) to conduct a pivotal clinical trial with the investigational new drug atacicept for the treatment of patients with lupus nephritis. This is one of two clinical studies intended to form part of the application for marketing authorization.

The randomized, double-blind placebo-controlled multi-center clinical trial will be conducted at sites in North America, Europe, Latin America, and Asia. Approximately 200 patients with active lupus nephritis will be enrolled in this trial, aimed at demonstrating the efficacy and safety of atacicept as compared to placebo.

"Together with Merck Serono, we concluded that an SPA provided the clearest path to ensure that this trial will support the application for atacicept marketing authorization," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer. "We're pleased to have reached agreement with the FDA about the design of this study and plan to begin enrolling patients in the fourth quarter of 2007."

In the SPA process, the FDA evaluates the design of clinical trials intended to form the basis of an efficacy claim to support a new drug application. The SPA provides a binding agreement between the FDA and a company that the study design, trial size, endpoints and data analyses plan, are acceptable to the FDA and are adequate to support a license application for marketing in the U.S.

ZymoGenetics and Merck Serono are developing atacicept as a potential treatment for autoimmune diseases and B-cell malignancies. Merck Serono is the study sponsor, however ZymoGenetics will operationally conduct the lupus nephritis study. The companies plan to conduct a second study in pat
'/>"/>

SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. UW-Madison to receive $125M for bioenergy research center
2. Madison to receive funding as part of $60M solar energy program
3. Software exec Jan Eddy to receive "Seize the Day" award
4. Medical College receives $377K to study brain disease
5. Lucigen receives $750K grant to boost biofuel yields
6. Medical College receives $1.4M cancer grant
7. Wisconsin biotech firm receives $107K NIH grant
8. InvivoSciences receives NIH grant for heart technology
9. Nations only stem cell bank will receive UC-San Francisco cell line
10. Medical College receives $11 million grant to study high blood pressure
11. Madison business receives $115,000 of new state biofuels funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... designed to introduce cutting edge communication technology, provide ... platform upgrades. This webinar series demonstrates online communication ... to leverage web conferencing’s most innovative and powerful ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
(Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD and ... on the growing mobile commerce market, announces it has retained ... for the 2015 International CES debut of the Wocket™ biometric ... be at the NXT-ID booth January 6th and 7 th ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... zebrafish embryos resulting from exposure to environmental toxins can ... published in the online open access journal Genome Biology. ... toxin can be read like a barcode, offering researchers ... toxin on developing vertebrate embryos. Zebrafish embryos were ...
... BUFFALO, NY -- Severely restricting calories leads to a ... has shown for the first time that such a ... slowing the seemingly inevitable progression to physical disability and ... of life-time caloric restriction, showed that the diet reduces ...
... housing developments sprout across the United States, smart growth ... pockets, instead of the more standard and familiar sprawl. ... the environment, affecting a smaller portion of the land ... cluster development was to protect open space, farmland, and ...
Cached Biology News:Decoding effects of toxins on embryo development 2Severely restricted diet linked to physical fitness into old age 2Location, location, location 2Location, location, location 3